Oral sphingosine 1-phosphate (S1P) 1 and 5 receptor agonist Zeposia (ozanimod) achieved all its targets in the True North trial involving adults with moderate-to-severe ulcerative colitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback